A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)

Inclusion Criteria: * Diabetes mellitus * Hypertension and has received losartan 50 mg or losartan 100 mg for at least 6 months * Microalbuminuria (defined as microalbuminuria \> 30 mg/g and \< 300 mg/g by spot urine test) * Serum creatinine ≤1.5 mg/dL for men and ≤1.4mg/dL for women * Urinalysis with white blood cells (WBC) \<5 cells per high power field * Results of hemoglobin A1c (HbA1c), fasting blood glucose, serum creatinine, urine albumin/urine creatinine ratio and urinary analysis tests at baseline and 6 months after initiating the losartan therapy are available * Medical history and co-morbidities (if available) listed in medical records * Prescription information of antihypertensive regimen of losartan 50 mg or 100 mg available Exclusion criteria: * Treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARB) before initiated treatment with losartan 50 mg or losartan 100 mg * Enrollment in another clinical trial